November 6, 2020 - Botulinum toxin - best known by the brand name Botox - is a popular treatment to reduce facial lines and wrinkles. Over the years, plastic surgeons have explored alternative approaches to maximize effectiveness while minimizing side effects of botulinum toxin injection, including smaller doses and more-diluted concentrations.
Now a team of plastic surgeons is developing an innovative, less-invasive "Microbotulinum" injection technique - using many tiny doses of botulinum toxin injected in a grid pattern just under the surface of the facial skin. In a preliminary report, this micro-dose technique provides objective improvement in skin texture and roughness, backed up by a high patient satisfaction rate.
The Microbotulinum technique is a safe and effective method of facial rejuvenation, yielding objective improvements of about 20 percent in skin texture, microroughness and pore size, according to the report by Alberto Diaspro, MD, MSc, of the Rigeneralab Centre for Regenerative Medicine in Turin, Italy, and colleagues. The researchers present a description and initial evaluation of their approach in the November issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).
Cosmetic botulinum toxin injection is by far the most common cosmetic procedure, performed about 7.7 million times in US patients in 2019, according to ASPS statistics. In the standard technique, a few injections are made to treat common problems such as frown lines, forehead creases and crow's feet around the eyes.
The new, less-invasive technique uses a series of tiny "blebs" of botulinum toxin A injected just under the skin surface. The injections follow a one-centimeter grid pattern, extending from the forehead to the cheek and down to the jawline. "This targets the superficial fibers of the facial muscles and weakens their insertion into the undersurface of the skin, which is responsible for the fine lines and wrinkles on the face and neck," Dr. Diaspro and colleagues write.
The researchers used a specialized, high-resolution "skin scanner" system to provide objective data on how the Microbotulinum procedure performed in improving the skin appearance. Graded on a 10-point scale (0 being best, 10 being worst), average skin texture improved from 6.0 to 4.0, while scores for skin "micro-roughness" improved from 7.5 to 5.0. There was a similar and significant reduction in enlarged pore size.
The improvements were backed up by subjective ratings: 90 days after micro-dose treatment, 95 percent of patients were satisfied or very satisfied with their results. As in any botulinum toxin procedure, the effects were temporary, lasting up to 120 days. After that, treatment would need to be reported in order to maintain the improvement.
The results of the Microbotulinum technique appeared best in middle-aged patients. Dr. Diaspro and colleagues believe it will be most appropriate for patients ranging from their mid-thirties to early fifties. The researchers emphasize the need for further studies to determine the optimal dose of botulinum toxin to produce a longer-lasting effect at the dilution used.
Click here to read "Microbotulinum: A Quantitative Evaluation of Aesthetic Skin Improvement in 62 Patients."
About Plastic and Reconstructive Surgery
For more than 70 years, Plastic and Reconstructive Surgery® (http://www.
The American Society of Plastic Surgeons is the largest organization of board-certified plastic surgeons in the world. Representing more than 7,000 physician members, the society is recognized as a leading authority and information source on cosmetic and reconstructive plastic surgery. ASPS comprises more than 94 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2019 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning and research and clinical intelligence. For more information about our solutions, visit https:/